Ligand Launches Redesigned Corporate Web Site
Ligand Pharmaceuticals, Inc. (Nasdaq:LGND), launched a fully redesigned public Web site at www.ligand.com. The site is designed around our new business model and provides increased functionality and interactivity.
"Our new Web site brings to life Ligand's core foundation, which is our science. Ligand has gone through significant changes this year, and we have expanded the content and redesigned the functionality of the Web site to reflect our new business strategy and opportunities," said John L. Higgins, President and CEO. "Our goal is to make this useful for investors, prospective corporate partners and future employees."
Ligand discovers and develops new drugs that address critical unmet medical needs of patients in the areas of thrombocytopenia, hepatitis C, cancer, hormone-related diseases, osteoporosis and inflammatory diseases. Ligand's proprietary drug discovery and development programs are based on its leadership position in gene transcription technology, primarily related to intracellular receptors.
This news release contains certain forward-looking statements by Ligand, including statements regarding the development of financial strategies and controls necessary for future growth, which involve risks and uncertainties and reflect Ligand's judgment as of the date of this release. Actual events or results may differ from Ligand's expectations. For example, we may not be able to timely or successfully transform the Company or advance any product(s) in our pipeline. In addition, we may not be able to successfully implement our strategy, and continue the development of our proprietary programs. Additional information concerning these and other risk factors affecting Ligand's business can be found in prior press releases available via the Company's web site, www.ligand.com, as well as in Ligand's public periodic filings with the Securities and Exchange Commission at www.sec.gov. Ligand disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Source: Ligand Pharmaceuticals Inc.
Released July 26, 2007